Emerging Technology and Uncharted Domains

Gaming and e-sports, pharmaceuticals and life sciences, artificial intelligence and data-intensive products share a common difficulty: regulation is incomplete, fragmented across states or actively in flux, and there is no settled market practice to follow. Advising here requires reasoning from first principles, an accurate reading of regulatory direction, and the willingness to commit to a defensible position and record the basis for it. We advise developers, adopters, licensors and investors on commercialising proprietary technology, and on the ownership questions artificial intelligence now forces on every content and data business — what the model was trained upon, who owns the output, what has been represented to the customer, what has been warranted to the investor, and where liability rests when the system is wrong.

Representative work: 

• Gaming, e-sports and skill-gaming licensing, structuring and state-wise analysis
• pharmaceutical and life sciences collaboration, licensing, clinical and regulatory advisory 
• technology transfer, know-how, engineering and plant supply agreements 
• software development, SaaS, API, escrow and open-source licensing 
• artificial intelligence product terms, training data, model licensing and output ownership 
• data protection and privacy compliance under the DPDP framework and cross-border regimes 
• platform terms of use, intermediary obligations and content moderation policy 
• digital assets, tokenisation and Web3 arrangements 
• health-tech, fin-tech and ed-tech regulatory positioning 
• first-instance advisory on business models without Indian precedent.